SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick mod ...

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company's Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™ (MCRR). At bo ...

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™ (MCRR). At b ...

Myriad Genetics, Inc. (MYGN) reported a loss of 1 cent per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 11 cents. The figure improved from the year-ago quarter’s loss of 21 cents.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.RevenuesTotal revenues rose 12% year over year to $202.2 million in the quarter under review. The figure topped the Zacks Consensus Estimate by 4.6 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O ...

财务数据和关键指标变化 - 公司实现了12%的收入同比增长,体现了内部举措的成效 [10][50] - 毛利率达到68.5%,同比提升80个基点,克服了一些收购资产的影响 [56][57] - 调整后的EBITDA为400万美元,去年同期为亏损1900万美元,盈利能力大幅改善 [58] - 调整后的每股收益亏损约0.1美元,去年同期亏损0.21美元,接近实现盈亏平衡 [58] 各条业务线数据和关键指标变化 - 遗传性癌症检测业务收入同比增长16%,检测量同比增长9% [23] - 产前检测业务收入同比增长22%,检测量同比增长9% [30] - 药物基因组学业务收入同比增长21%,检测量约12.4万例 [33] 各个市场数据和关键指标变化 - 公司正在重组国际业务,将EndoPredict业务出售给Eurobio Scientific,并授权其在美国以外销售Prolaris体外诊断试剂 [16][17] - 这有助于公司更有效地支持生物制药合作伙伴,并通过战略合作伙伴关系更有效地推广其他全球业务 [17] 公司战略和发展方向及行业竞争 - 公司正在加快投资、临床验证研究和电子病历系统集成,以提高产品的临床价值和有效性 [12] - 公司认为FDA最终规则对其有利,因为公司的所有临床检测都符合CAP/CLIA和纽约州的要求,有较强的质量保证体系 [19][45][46] - 公司正在整合Precise Tumor和Precise Liquid产品,并将其纳入新的实验室,以增强肿瘤业务 [18][41][42][43][44] 管理层对经营环境和未来前景的评论 - 公司对2024年的增长和盈利能力保持乐观,认为可以实现或超过收入指引范围 [60][61] - 公司将加大一些可以带来可操作商业机会的投资,如电子病历系统集成等 [61] - 公司认为FDA新规将成为其的竞争优势,因为满足新要求的成本较高 [87][88][89] 问答环节重要的提问和回答 问题1 **Matthew Sykes 提问** 询问公司在遗传性癌症和产前检测业务的市场份额增长空间 [70][71] **Paul Diaz 和 Mark Verratti 回答** 公司认为这些业务的市场份额增长机会较大,但需要一定时间,预计在2025年能够充分体现 [72][73][74] 问题2 **Doug Schenkel 提问** 询问新任高管对公司的初步评估和发现 [81][82][83][84] **Scott Leffler 和 Sam Raha 回答** 新任高管对公司的转型和发展前景感到乐观,认为公司具备强大的产品和团队实力 [85][86] 问题3 **Rachel Vatnsdal 提问** 询问ACOG指南更新对公司产前检测业务的影响 [126][127][128] **Paul Diaz 回答** 公司认为ACOG指南更新将有利于扩大产前检测业务的市场份额和提升平均销售价格 [127][128]

For the quarter ended March 2024, Myriad Genetics (MYGN) reported revenue of $202.2 million, up 11.6% over the same period last year. EPS came in at -$0.01, compared to -$0.21 in the year-ago quarter.The reported revenue represents a surprise of +4.55% over the Zacks Consensus Estimate of $193.4 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +90.91%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall St ...

Myriad Genetics (MYGN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 90.91%. A quarter ago, it was expected that this molecular diagnostic company would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four quarters, t ...

Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 megan.manzari@myriad.com matt.scalo@myriad.com Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16 ...